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Detection by phenotyping of the production of metallo-~-Iactames by 
Pseudomonas aeruginosa in Cystic Fibrosis patients 
A. Bisiklis 1, M. Fat oulakJ ~, R Tsiout sias 1, St. Alexiou D~aiel 1, S. Nousi~Ar vanit akJs ~ 
iDepartrnent of Microbiology, AHEPA University Hospital, School of Medicine, 
Thessaloniki, Greece; 2Fourth Pediatric Department, Aristotle University of 
Thessaloniki, Greece 
Introduct ion:  Metal lo [~ lactamases are enzymes which can be produced by 
Pseudomonas aeruginosa strains mad they represent one of the drug resistance 
mechanisms to imipenem. 
Objective: The purpose of our study was to determine the production of metal lo [~ 
lactamases by Pseudomonas aeruginosa strains isolated from sputum cultures 
obtained from patients with cystic fibrosis. 
Mater ia l s  and  Methods:  Samples of 45 Pseudomonas aeruginosa strains collected 
during the year 2003 were studied. 33 strains appeared homogeneous resistance to 
Imipenem whi le  the remaining 12 strains appeared to have intermediate r sistance. 
The identification was performed by API 20NE method. The determination of 
antibiotic sensitivity was performed by Vitek 2 method. The detection of metal lo [~ 
lactamases production was performed by E test MBL  (Imipenem (IP) / Imipenem + 
EDTA (IPI)) a rAB Biodisk. 
Results: Ten strains were found to produce metallo [~ lactamases, 3 strains gave 
undetermined results, whi le  32 strains were negative. Four positive and 1 
undetermined strains were found to have intermediate r sistance to imipenem. Six 
positive mad 2 undetermined strains were found to have homogeneous resistance to 
imipenem. 
Conclusions: a) The percentage of metal lo [~ lactamases producing strains was 
22% b) It is remarkable that the percentage detection of producing metallo [~ 
lactamases was higher ha strains with intermediate r sistance than strains with 
homogeneous resistance to Imipenem. 
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Hypermutable Pseudomonas aeruginosa strains in cystic fibrosis 
pafients: A link with antibiotic resistance 
B. ~ener 1,A. @akar 1, U. 0 zx2elik ~, D. Dogm ~, E. 5aal~in ~,D. G/it a, A. Asian 2, N. 
Kipe r2 
Hacettepe University Medical Faculty, A~ara, Turkey, ~Dept. Of Clinical 
Microbiology, 2ChiMren's Hospital Dept. Of Chest Diseases, SChiMren's Hospital 
Microbiology Laboratory 
Aim:  Antimicr obial therapy administered to CF patients with chronic t~aeruginosa 
lung infection, leads to the selection of multiply resistant ~aeruginosa strains. 
Resistance to antibiotics has been associated with the hypermut able phenotype. This 
study was conducted to detect he presence of hyper mut ator t~aeruginosa trains in 
CF patients and to guide the treatment accordingly. 
Methods:  Susceptibil ity testing of 80 t~aeruginosa strains for aztreonam, 
ceftazidime, imipenem, meropenem, amikacin, tobramycin and ciprofioxacin was 
performed by disk diffusion. The presence of resistant mutant subpopulations 
within the hahibition zones was recorded alter 36 hrs. of incubation and mutant 
colonies for each antibiotic were retested. The presence of mutant colonies for three 
or more antibiotics identified the strain as hypermutable. The mutation frequencies 
were estimated by standard methods for confirmation of hyper mutable phenotype. 
Results: Among the study population 26 strains (32.5%) were found to be 
hypermutable. Mutant colonies were detected most frequently for imipenem and 
meropenem. Hypermutable isolates were more resistant to aztreonam, imipenem 
and t obr amycin than nonhyper mutables. Cipr ofioxacin and amikacin were the most 
active agents against the hypermutable ones. 
Conclusions: Since hypermutable isolates were more frequently associated to 
antibiotic resistance, their detection is of crucial importance. Thus, the incubation 
period for CF t~aeruginosa antibiogr ams should be prolonged to 36 hours to detect 
the mutant s'ubpopulations and to recommend combination therapy in such cases to 
minimize the development of resistance. 
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Increasing antibiotic resistance amongst pseudomonas sb~ains in 
one UK adult CF unit 
C. McManus, K. Mohan, M.J. Ledson, M.J. Walshaw 
RegionaI AduIt CF Unit, The Cardiotlu)racic Centre, Liverpool UK 
In rmduct lon :  Transmissible strains of Pseudomonas aeruginosa are becoming 
increasingly recognized, and the commonest ha the UK is the Liverpool epidemic 
strain (LES), which is prevalent amongst CF patients ha Liverpool. We have already 
shown that LES is frequently multiresistant compared to other (unique) strains, but 
how resistance patterns have developed over t ime is unknown. To investigate this 
further, over a 6 year period we compared the antibiogr ams of patients attending the 
Liverpool adult CF clinic infected by LES and unique strains, looking for any 
change ha resistance to common antipseudomonal antibiotics. 
Method. Antibiograms to 5 common antipseudomonal ntibiotics (ceftazidime 
[cef], meropenem [met], tobramycin [tab], aztreonam [azt], and colomycin [col]) 
were compared in 1998 and 2CO4 for 29 patients chronically infected with 
Pseudorrmnas aeruginosa (15 LES, 14 unique strains). Where sputum samples 
produced multiple phenotypes, only those with the most resistant antibiogr ams were 
selected to mirror the clinical scenario. 
Resulrs. For both LES and unique groups, the antibiograms overall showed an 
increasing pattern of resistance from 1998 to 2CO4 (see table). However, sputum 
samples from LES patients were much more antibiotic resistant han those with 
unique strains: 
Antibiotic (% sensitive) Cef Mer Tab Azt Col 
Unique 1998 92.3 91.7 92.9 85.7 1(30 
2004 71.4 78.6 85.7 71.4 1(30 
LES 1998 49.9 64.3 1(30 35.7 1(30 
2004 46.6 53.3 90.9 96.7 1(30 
Conclusion: This study confirms that there is increasing resistance to antibiotics 
amongst Pseudomonas aeruginosa str ins in CF patients in the UK,  although strains 
appear to still be sensitive to colomycin. This work confirms the importance of 
using antibiotics rationally, and wherever possible preventing the spread of 
transmissible strains. 
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Mucoid Pseudomonas aeruginosa infection, antibiotic resistance, and 
lung disease progression in children with cysfic fibrosis 
P.M. Farrell, Z. Li, M.R. Kosor ok, A. Laxova, J. Collins 
Univ of Wisconsin Medical School, Madison, WI USA 
Although Pseudomonas aerugionosa (PA) is the most common virulent cbronic 
respiratory pathogen in cystic fibrosis (CF), longitudinal development of mucoid 
PA (MPA) infection, development of antibiotic resistance, and lung disease 
progression in children with CF remain to be defined precisely. Our objective is to 
elucidate the t iming of non mucoid (non MPA) and MPA infections, their impact on 
lung disease, and the determinants of aminoglycoside r sistance. We evaluated from 
birth to age 16 years a total of 56 CF patients alter diagnosis tbr ough the Wisconsin 
CF Neonatal Screening Project. The t iming of non MPA and MPA acquisition was 
assessed by cultures, as wel l  as serial PA serology data. We found that 30% of 
patients acquired non MPA during the first 6 months of life, and the age specific 
prevalence of MPA increased from age 4 to 16 years. Non MPA and MPA were 
acquired at median ages of 1.0 and 13.0 years, respectively. The relatively long 
transition t ime from non MPA to MPA could be extended for 3 years (p .03) by 
anti PA antibiotic treatment. Evaluation of aminoglycoside r sistance revealed that 
the age specific prevalences of gentamic in and tobramycin non sensitivity 
(intermediate or resistant) were 23% and 8% at age 2 yrs, 31% and 6% at 6 yrs, 31% 
and 19% at 10 yrs, mad 80% and 40% at 16 yrs, respectively. The median t ime to 
aminoglycoside non sensitivity was 12.5 years. We are currently studying the 
determinants of antibiotic resistance. We conclude that there is a relatively long 
window of opporttmity for possible eradication of initial non MPA infections, 
particularly with aggressive anti PA therapy. This is important because our data 
reveal that MPA plays a much greater ole in CF lung disease progression than non 
MPA. 
